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better morphological assessment of 
the malignant cell population and per-
mits immunohistochemsitry.2 This is 
the preferred method to prepare cell 
blocks worldwide.2–4 Current molecu-
lar pathology guidelines from the 
College of the American Pathologists, 
International Association for the Study 
of Lung Cancer, and the Association for 
Molecular Pathology recommend the 
use of cell blocks for molecular testing 
and therapy selection criteria for epi-
dermal growth factor receptor (EGFR) 
tyrosine kinase inhibitors and anaplas-
tic lymphoma kinase inhibitors.1
Plasma of course contains cell-
free DNA.5 Plasma sources vary between 
laboratories (human, rabbit, etc.) as does 
the volume of plasma used to form cell 
blocks.3,4 To identify the level of DNA 
contamination in cell blocks, we have 
analyzed DNA extracted from cell-free 
plasma thrombin cell blocks and blank 
(tissue free) histological parafﬁn blocks 
using routine molecular techniques includ-
ing an in-house PCR/Pyrosequencing 
and a Qiagen Therascreen EGFR RGQ 
PCR Kit. DNA product was detected in 
the elute extracted from the empty cell 
blocks; however, no DNA was detected in 
the control parafﬁn blocks.
We conclude that plasma is a source 
of contaminating DNA. Fortunately, a 
review of our molecular assays performed 
on cell blocks found no evidence of false-
positive or false-negative results. As high 
throughput Next Generation Sequencing 
platforms make their way into routine 
diagnostic practice, their superior sensi-
tivity in DNA mutation detection in the 
presence of any extraneous DNA might 
generate false-positive results and impact 
on the molecular diagnosis. Given the 
potential for extraneous DNA to affect 
molecular assays, we believe that the 
plasma thrombin clot technique should 
no longer be used when molecular testing 
is to be undertaken, and that pathology 
laboratories should change their process-
ing techniques accordingly.
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To the Editors:
Molecular testing to personalize 
therapy is an essential part of the investi-
gation of cancer to personalize anticancer 
therapy.1 Availability of sufﬁcient tissue 
is important, and in some settings, for 
example, lung cancer diagnosed by bron-
choscopic biopsy or ultrasound guided 
cytology, this may be challenging.
For cytological specimens, resid-
ual material remaining after the initial 
diagnostic slide can be made into a 
cell block. In most pathology labo-
ratories, these are prepared by using 
plasma to form a clot entrapping the 
cells followed by embedding into par-
afﬁn wax. Sections from this allow 
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To the Editor:
The epidermal growth factor receptor 
(EGFR) gatekeeper mutation T790M is 
associated with resistance against ﬁrst- 
and second-generation EGFR tyro-
sine kinase inhibitors in patients with 
advanced non–small-cell lung cancer.1 
The third-generation inhibitor AZD9291 
can overcome T790M-mediated resis-
tance in patients, as shown by a recent 
clinical trial.2 T790M can be detected 
in tumor tissue, circulating tumor cells, 
and circulating tumor DNA.3–5 Here, we 
report on a ﬁrst patient with AZD9291 
therapy based on circulating T790M.
In 2015, we established an IRB-
approved research collaboration with 
NEO New Oncology AG (Cologne, 
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Germany), to implement their circulat-
ing tumor DNA-based assay NEOLiquid. 
This assay covers clinically relevant 
genomic alterations, such as mutations, 
fusions, and copy number alterations of 
31 genes. One of the ﬁrst patients tested 
was a 53-year-old never-smoker with 
metastatic lung adenocarcinoma and 
EGFR exon 19 deletion diagnosed in 
2012. He had been extensively pretreated 
with EGFR- tyrosine kinase inhibitors, 
chemotherapy, neurosurgery, and brain 
radiation. Previous attempts to detect 
T790M in tumor rebiopsies by conven-
tional sequencing failed. The patient con-
sented to testing, and T790M was found 
in plasma (allele frequency, AF = 39%), 
along with the exon 19 deletion 
(AF = 28%). We received permission 
from AstraZeneca and Swissmedic for 
compassionate use of AZD9291, and the 
patient started on a daily dose of 80 mg. 
Within a few days, his clinical condi-
tion improved. After 6 and 12 weeks, 
18F-deoxyglucose positron emission 
tomography with computer tomogra-
phy showed tumor response (Fig. 1A–F). 
Further plasma samples drawn every 
2 weeks were analyzed, showing gradual 
decrease of the T790M, and complete 
molecular remission after 10 weeks 
(Fig. 2). Retrospective analysis of the 
brain metastasis revealed T790M, but 
with very low AF of 0.2%. Currently, 
AZD9291 therapy is ongoing, tolerability 
is excellent, and there is no clinical, radio-
logical, or genomic evidence of tumor 
progression.
We conclude that blood genomic 
tests can complement tissue biopsy, are 
suitable for therapy monitoring, and 
deserve consideration as companion 
diagnostics for mutation-selective can-
cer drugs.
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fIGURE 2. Allele frequency of EGFR T790M in the plasma by NEOLiquid (NEO New Oncology AG, Cologne, Germany) before 
the start of AZD9291 treatment (A), and after 2 weeks (B), 4 weeks (C), 6 weeks (D), and 12 weeks (E). The vertical dashed black 
line depicts the positional nucleotide change of C>T in exon 790 of EGFR, resulting in the T790M mutation.
fIGURE 1. A–C, Pretreatment 18FDG-PET/CT showing the primary tumor in the right lung, disseminated nodal and skeletal 
metastases, with strong uptake in the fourth thoracic vertebrae (B), and in the left sacrum and ilium (C). 18FDG-PET/CT at 6 weeks 
(D–F) and 12 weeks (G–I) weeks after start of treatment with AZD9291, showing metabolic and morphological tumor response, 
and persistent pleural effusion (E). 18FDG-PET/CT, 18F-deoxyglucose positron emission tomography with computer tomography.
